Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research

Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eftilagimod alpha is a large-molecule cancer drug consisting of the four extracellular domains of lymphocyte activation gene-3 (LAG-3) fused to the Fc region of an IgG1(LAG-3Ig). Eftilagimod alpha binds preferentially to a subset of MHC class II molecules that are enriched in lipid rafts and/or composed of stable peptide-MHC II (pMHCII) complexes. On T cells, membrane-anchored LAG-3 is an inhibitory receptor downregulating T-cell receptor (TCR) signaling. Eftilagimod alpha is an MHC class II agonist and therefore a dendritic-cell activator, causing increased antigen presentation to cytotoxic (CD8+) T cells. In the absence of antigen presentation via MHC class II molecules, Eftilagimod alpha reactivates dormant antigen-experienced memory T cells, allowing them to recognize their antigen targets at the tumor site.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-828-1mg	1mg	3090
GMP-Bios-INN-828-10mg	10mg	Inquiry
GMP-Bios-INN-828-100mg	100mg	Inquiry
GMP-Bios-INN-828-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant)
INN Name	Eftilagimod Alfa
Target	MH2
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [LAG3 (lymphocyte activating 3, lymphocyte- activation 3, CD223)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [LAG3 (lymphocyte activating 3, lymphocyte- activation 3, CD223)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Prima BioMed (Sydney NSW Australia)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0